Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations

Authors: Kron, Anna, Scheffler, Matthias, Wiesweg, Marcel, Hummel, Horst-Dieter, Kulhavy, Jonas, Gatteloehner, Stefan, Kollmeier, Jens, Schubart, Christoph, Groß, Thorben, Demes, Melanie-Christin, Keymel, Stefanie, Joosten, Maria, Merkelbach-Bruse, Sabine, Wölwer, Christina Bianca, Tufman, Amanda, Kauffmann-Guerrero, Diego, Oeser, Katharina, Zehaczek, Melanie, Jeratsch, Ulli, Wolf, Juergen

Source: In European Journal of Cancer August 2024 207

Corrigendum to “Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations” [Eur J Cancer 207 (2024) 114158]

Authors: Kron, Anna, Scheffler, Matthias, Wiesweg, Marcel, Hummel, Horst-Dieter, Kulhavy, Jonas, Gatteloehner, Stefan, Kollmeier, Jens, Schubart, Christoph, Groß, Thorben, Demes, Melanie-Christin, Keymel, Stefanie, Joosten, Maria, Merkelbach-Bruse, Sabine, Woelwer, Christina Bianca, Tufman, Amanda, Kauffmann-Guerrero, Diego, Oeser, Katharina, Zehaczek, Melanie, Jeratsch, Ulli, Wolf, Juergen

Source: In European Journal of Cancer December 2024 213